IKS073
Solid tumors (Lung, Esophagus, H&N, Colorectal, Stomach, Breast, Cervix)
Pre-clinicalActive
Key Facts
Indication
Solid tumors (Lung, Esophagus, H&N, Colorectal, Stomach, Breast, Cervix)
Phase
Pre-clinical
Status
Active
Company
About Iksuda Therapeutics
Iksuda Therapeutics is a clinical-stage biotech specializing in next-generation antibody-drug conjugates (ADCs) with a mission to design the optimal ADC for specific cancer targets rather than being technology-led. The company has built a pipeline featuring both clinical-stage assets targeting known antigens like CD19 and HER2, and a next-wave pipeline utilizing its proprietary ProAlk payload platform. With a world-class R&D team and a flexible technology model, Iksuda aims to become a partner of choice in the ADC space while advancing therapies for cancers with high unmet need.
View full company profile